AstraZeneca CFO Dr Aradhana Sarin Breaks Down Revenue Growth Goals

Why It Matters

The plan signals a potentially transformative earnings boost for investors and intensifies competition in oncology and cardiovascular markets, while the NYSE listing reduces capital‑raising friction in the world’s largest investor base.

Key Takeaways

• AstraZeneca targets $80 bn revenue by 2030, doubling current size.
• Investing $15 bn annually in R&D to fuel pipeline expansion.
• Over 120 phase‑3 trials underway, eight FDA approvals this year.
• Ordinary shares now listed on NYSE, boosting US investor access.
• New hypertension drug launched in U.S., addressing 7 million patients.

Summary

AstraZeneca’s chief financial officer, Dr. Aradhana Sarin, used a NYSE listing ceremony to outline the company’s aggressive growth roadmap, highlighting a $80 billion revenue ambition for 2030 and the strategic shift to ordinary shares on the New York Stock Exchange.

The CFO said the firm will double its current sales by investing roughly $15 billion a year in research and development. With more than 120 phase‑3 trials in progress and eight FDA approvals already this year, the pipeline spans oncology, rare diseases, cardiovascular and a newly launched hypertension drug expected to serve 7 million patients.

Sarin noted that about 45 % of AstraZeneca’s shareholders are now based in the United States, a shareholding mix that the ordinary‑share listing is designed to deepen. She also emphasized the mix of lower‑risk extensions of existing products and 20 new molecular entities, ten of which have already received approval.

If the targets are met, AstraZeneca will cement its position as a leading biopharma player, offering investors a growth story backed by robust R&D spend and broader access to U.S. capital markets, while delivering a larger portfolio of high‑value medicines.

Original Description

AstraZeneca CFO Dr. Aradhana Sarin joins NYSE Live to discuss her company's goals for revenue growth